Plain-English translation of NCT07214532 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Neoplasms research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial tests whether a special blood test called Signatera can help doctors decide when to start ribociclib or abemaciclib (medications that block cancer cell growth) in people with early-stage breast cancer. Instead of giving everyone the medication automatically, researchers want to use the blood test to detect any remaining cancer cells in your bloodstream and only add the medication if needed. This approach may help some patients avoid unnecessary side effects while keeping them just as safe.
Not everyone with intermediate-risk breast cancer benefits equally from adding this medication to their hormone therapy, and some people experience side effects they may not need. This trial aims to find out whether using a blood test to personalize treatment timing can maintain effectiveness while reducing unnecessary treatment for those who don't have signs of remaining cancer.
You likely qualify if…
You likely don't qualify if…
You will start hormone therapy and have a blood test to check for remaining cancer cells. If cancer cells are detected in your blood, you'll begin taking the additional medication along with your hormone therapy. If no cancer cells are found, you'll continue hormone therapy alone with follow-up blood tests every three months. Throughout the study, you'll have regular clinic visits and monitoring for up to nine years to track how well this approach works.
AI-generated summary from trial data · Sep 20, 2026 · Not medical advice
United States